These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 21410736

  • 1. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
    Helin-Salmivaara A, Korhonen MJ, Alanen T, Huupponen R.
    J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jönsson B, IDEAL Trial Investigators.
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [Abstract] [Full Text] [Related]

  • 3. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
    Swindle JP, Potash J, Kulakodlu M, Kuznik A, Buikema A.
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
    [Abstract] [Full Text] [Related]

  • 4. Long-term persistence with statin therapy: a nationwide register study in Finland.
    Helin-Salmivaara A, Lavikainen P, Korhonen MJ, Halava H, Junnila SY, Kettunen R, Neuvonen PJ, Martikainen JE, Ruokoniemi P, Saastamoinen LK, Virta L, Huupponen R.
    Clin Ther; 2008 Dec; 30 Pt 2():2228-40. PubMed ID: 19281917
    [Abstract] [Full Text] [Related]

  • 5. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
    Hussein MA, Chapman RH, Benner JS, Tang SS, Solomon HA, Joyce A, Foody JM.
    Am J Cardiovasc Drugs; 2010 Dec; 10(3):193-202. PubMed ID: 20387911
    [Abstract] [Full Text] [Related]

  • 6. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
    Sedjo RL, Cox ER.
    Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
    Simpson RJ, Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A.
    Mayo Clin Proc; 2009 Dec; 84(12):1065-72. PubMed ID: 19955243
    [Abstract] [Full Text] [Related]

  • 9. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.
    Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.
    Curr Med Res Opin; 2008 Jul; 24(7):1987-2000. PubMed ID: 18554430
    [Abstract] [Full Text] [Related]

  • 10. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
    Ara R, Pandor A, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, Wierzbicki AS, Stevenson M.
    Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076
    [Abstract] [Full Text] [Related]

  • 11. The value of atorvastatin over the product life cycle in the United States.
    Grabner M, Johnson W, Abdulhalim AM, Kuznik A, Mullins CD.
    Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
    [Abstract] [Full Text] [Related]

  • 12. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).
    Pedersen TR, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Lindahl C, Szarek M.
    Am J Cardiol; 2010 Aug 01; 106(3):354-9. PubMed ID: 20643245
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Aug 01; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 14. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
    Brun J, Ohlsson-Onerud A, Sörensen N.
    Lakartidningen; 2008 Aug 01; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.
    Simpson RJ, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A.
    Am J Ther; 2011 Nov 01; 18(6):436-48. PubMed ID: 20802306
    [Abstract] [Full Text] [Related]

  • 16. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
    Chodick G, Shalev V, Gerber Y, Heymann AD, Silber H, Simah V, Kokia E.
    Clin Ther; 2008 Nov 01; 30(11):2167-79. PubMed ID: 19108805
    [Abstract] [Full Text] [Related]

  • 17. Pattern of statin use among 10 cohorts of new users from 1995 to 2004: a register-based nationwide study.
    Helin-Salmivaara A, Lavikainen PT, Korhonen MJ, Halava H, Martikainen JE, Saastamoinen LK, Virta L, Klaukka T, Huupponen R.
    Am J Manag Care; 2010 Feb 01; 16(2):116-22. PubMed ID: 20148616
    [Abstract] [Full Text] [Related]

  • 18. Dose-related effect of statins on atrial fibrillation after cardiac surgery.
    Kourliouros A, De Souza A, Roberts N, Marciniak A, Tsiouris A, Valencia O, Camm J, Jahangiri M.
    Ann Thorac Surg; 2008 May 01; 85(5):1515-20. PubMed ID: 18442529
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.
    Hess G, Sanders KN, Hill J, Liu LZ.
    Am J Manag Care; 2007 Jun 01; 13 Suppl 3():S80-5. PubMed ID: 17596116
    [Abstract] [Full Text] [Related]

  • 20. Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
    Holme I, Szarek M, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group.
    Eur J Cardiovasc Prev Rehabil; 2009 Jun 01; 16(3):315-20. PubMed ID: 19322096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.